kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
356
JPY
-5
(-1.39%)
Jan 29, 3:06 pm JST
2.32
USD
Jan 29, 1:06 am EST
Result
PTS
outside of trading hours
355.8
Jan 29, 3:07 pm JST
Summary Chart Historical News Financial Result
PER
PBR
14.0
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
361 JPY 2.35 USD
Previous Close Jan 28
361 JPY 2.36 USD
High Jan 29, 9:00 am
361 JPY 2.35 USD
Low Jan 29, 12:48 pm
343 JPY 2.24 USD
Volume
1,878,900
Trading Value
0.66B JPY 4.30M USD
VWAP
350.05 JPY 2.29 USD
Minimum Trading Value
35,600 JPY 232 USD
Market Cap
0.04T JPY 0.27B USD
Number of Trades
1,135
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
2,949
1-Year High Jul 17, 2025
31,879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 1,799,400 11,969,200 6.65
Jan 16, 2026 1,744,800 10,737,600 6.15
Jan 9, 2026 1,706,400 10,219,100 5.99
Dec 26, 2025 1,731,600 9,410,400 5.43
Dec 19, 2025 1,862,000 9,892,900 5.31
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.